The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,318.00
Bid: 1,318.50
Ask: 1,319.50
Change: 35.50 (2.77%)
Spread: 1.00 (0.076%)
Open: 1,296.00
High: 1,321.00
Low: 1,296.00
Prev. Close: 1,282.50
PSN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

14 Apr 2016 07:00

RNS Number : 1352V
Persimmon PLC
14 April 2016
 

 

TRADING UPDATE

 

THURSDAY 14 APRIL 2016

 

Persimmon plc ("the Company") will hold its Annual General Meeting ("AGM") at 12.00 noon today at York Racecourse when the Chairman will make the following statement regarding current trading, financial performance and the outlook for the current financial year. This statement covers the period from 1 January 2016 to date and supplements the update given with the 2015 Final Results on 23 February 2016.

 

Consumer confidence is being supported by the continued progress made by the UK economy. The Group remains focussed on delivering family housing across the UK, excluding central London, to meet the continued demand for new homes at affordable prices. The number of customers visiting our development sites across the UK in the period was c.12% ahead of last year. Mortgage lenders remain keen to offer customers the opportunity to access mortgage credit on very attractive terms. Cancellation rates have continued to run at historically low levels.

 

We brought forward a healthy order book into 2016 and our strong sales performance over the period has resulted in total forward sales revenue, including legal completions taken so far in 2016, being 8% higher than last year at £2.15 billion (2015: £2.00 billion). Our weekly private sales rate per site over this period was 6% ahead of last year. We have 7,598 new homes sold forward into the private sale market for 2016 with an average selling price of c. £220,000, an increase of 5.8% over the prior year.

 

We are currently developing 370 active outlets across the UK, having opened 75 of the 100 new sites planned for the first half of the year. The Group continues to build new homes on all sites where an implementable detailed planning consent has been secured. Planning delays continue to erode the total number of active outlets being developed by the industry, hindering the drive to increase the volume of newly built homes delivered to the market. We are working hard to increase our active outlet numbers towards c.400 by the end of 2016 and will continue to focus on increasing our output to meet market demand. The Group has continued to invest in high quality new land in support of its future growth.

 

The Directors are pleased to announce that the Company has recently concluded an amendment of its £300m Revolving Credit Facility with the Company's five relationship banks, extending its maturity date to 31 March 2021.

 

Growing the business as market conditions allow whilst exercising capital discipline through the cycle is at the heart of the Group's strategy launched in early 2012. An important aspect of this capital discipline is our commitment to return surplus capital to shareholders over the long term.

 

The fourth payment of the Capital Return Plan of £338 million, or 110p per share, was brought forward and paid as a dividend on 1 April 2016. In addition, on 23 February 2016 the Board announced an increase of £860 million, or 45%, to the original Capital Return Plan, increasing the total value of the plan to c. £2.76 billion or £9.00 per share to be returned to shareholders by the end of 2021.

 

Since the launch of the new strategy in early 2012 the Group has delivered a 56% increase in new homes completed, invested over £2,200 million in new land, and opened 812 new development sites. We have also returned a total of £1,071 million of surplus capital to shareholders, over £550m higher than was originally planned.

 

The Group is in a strong position to continue to make good progress over future periods.

 

We will provide a further report in our Trading Update on Tuesday 5 July 2016.

 

For further information please contact:

 

Jeff Fairburn, Group Chief Executive

Simon Rigby

Mike Killoran, Group Finance Director

Kevin Smith

Persimmon plc

Jos Bieneman

Tel: +44 (0) 20 7638 9571 on the day

Citigate Dewe Rogerson

Tel: +44 (0) 1904 642199 thereafter

Tel: +44 (0) 20 7638 9571

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGMGMDNFMGVZM
Date   Source Headline
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company
8th Nov 20237:00 amRNSAppointment of Chief Financial Officer
7th Nov 20237:00 amRNSQ3 Trading Statement
3rd Nov 20231:15 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
10th Aug 20237:04 amRNSHalf Year Results
27th Jul 202310:13 amRNSDirectorate Change
10th Jul 20239:27 amRNSDirector Declaration
3rd Jul 20232:46 pmRNSTotal Voting Rights
1st Jun 20234:38 pmRNSTR-1: Notification of major holdings
1st Jun 20231:07 pmRNSBlock listing Interim Review
1st Jun 202311:06 amRNSTotal Voting Rights
3rd May 20235:00 pmRNSHolding(s) in Company
3rd May 20234:12 pmRNSDirector/PDMR Shareholding
2nd May 202311:13 amRNSTotal Voting Rights
26th Apr 20234:32 pmRNSResult of AGM
26th Apr 20237:00 amRNSQ1 Trading Statement
3rd Apr 20234:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20233:05 pmRNSTotal Voting Rights
27th Mar 20233:44 pmRNSDirector/PDMR Shareholding
22nd Mar 20233:00 pmRNSAnnual Report 2022 and Notice of AGM 2023
13th Mar 20231:57 pmRNSDirectorate Change
13th Mar 202312:19 pmRNSUK Government Self Remediation Contract Signed
7th Mar 20235:33 pmRNSHolding(s) in Company
7th Mar 20237:04 amRNSDirector Declaration
6th Mar 20235:02 pmRNSHolding(s) in Company
1st Mar 20237:00 amRNSFull Year Results
12th Jan 20237:00 amRNSTrading Statement
1st Dec 20225:30 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20225:25 pmRNSVoting Rights and Capital
8th Nov 20227:00 amRNSTrading Statement
1st Nov 20221:00 pmRNSTotal Voting Rights
1st Nov 20229:24 amRNSHolding(s) in Company
10th Oct 20222:24 pmRNSDirector/PDMR Shareholding
5th Oct 202210:26 amRNSHolding(s) in Company
4th Oct 20223:07 pmRNSDirector/PDMR Shareholding
3rd Oct 20222:12 pmRNSTotal Voting Rights
22nd Sep 20223:54 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.